(PharmaNewsWire.Com, April 15, 2017 ) Increase in prevalence of cancer across the globe and favourable government policies are the factors fuelling the market growth. Whereas factors like lack of skilled professionals is restraining the market. Oncology segment is anticipated to grow at higher CAGR during forecast period owing to the expirations of existing patent. North America accounted for the highest market share as compared to other regions owing to favourable government policies. Asia pacific region is expected to show healthy growth rate during forecast period.
Some of the key players in the market include Valeant Pharmaceuticals International, Inc., Novartis, Pfizer Inc., Turing Pharmaceuticals, Teva Pharmaceutical Ltd., Mylan N.V., Akorn, Inc., Mallinckrodt, Intellipharmaceutics and Alvogen.
Route of Administration Covered: -Topical -Parenteral -Oral -Other Route of Administration
Regions Covered: -North America -US -Canada -Mexico -Europe -Germany -France -Italy -UK -Spain -Rest of Europe -Asia Pacific -Japan -China -India -Australia -New Zealand -Rest of Asia Pacific -Rest of the World -Middle East -Brazil -Argentina -South Africa -Egypt
Company Profiling 10.1 Valeant Pharmaceuticals International, Inc. 10.2 Novartis 10.3 Pfizer Inc. 10.4 Turing Pharmaceuticals 10.5 Teva Pharmaceutical Ltd. 10.6 Mylan N.V. 10.7 Akorn, Inc. 10.8 Mallinckrodt 10.9 Intellipharmaceutics 10.10 Alvogen
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
